Last updated: February 20, 2026
What is the scope of patent CA2635378?
Patent CA2635378, filed in Canada, covers a pharmaceutical composition or method related to the treatment of specific medical conditions. It claims a novel compound or combination and its use for medical indications. The patent's scope predominantly includes:
- A specific chemical entity or a class of compounds.
- Methods of preparation and formulation.
- Therapeutic use for targeted conditions, possibly including indications like cancer, autoimmune diseases, or infectious diseases.
The precise composition claims extend to both the molecular structure and its formulations, with claims potentially covering methods of administration and dosage regimes.
How broad are the claims?
The claims are relatively narrow or broad depending on their phrasing:
- Compound claims specify the chemical structure with certain substituents, limiting scope to the particular molecular features.
- Use claims may cover methods of treatment using the compound, broadening the scope to medical applications.
- Formulation claims include compositions combining the compound with excipients, potentially broadening patent coverage to pharmaceutical preparations.
The patent possibly includes dependent claims that narrow the scope further (e.g., specific substituents, dosages), while independent claims define the broadest scope of the invention.
Patent claims and their key features
| Claim Type |
Focus |
Examples |
| Compound |
Chemical structure |
A benzodiazepine derivative with substituents X and Y |
| Use |
Medical application |
Use of the compound for treating autoimmune disease Z |
| Formulation |
Pharmaceutical composition |
A tablet including the compound and excipients A, B |
Claims around the chemical structure are standard for pharmaceutical patents. Use claims are critical for protection of medical indications. Formulation claims protect the method of delivering or administering the drug.
Patent landscape overview in Canada
The Canadian patent landscape for drugs is characterized by:
- Stringent patentability criteria, requiring novelty, inventive step, and utility (per Canadian Patent Act).
- An examination process that emphasizes clarity and support in the specification.
- A limited patent term of 20 years from the filing date, with potential extensions for patent term adjustments.
Globally, this patent landscape aligns with US and European standards but may encounter distinct challenges during examination related to the inventive step, especially if similar compounds are publicly known.
Patent family and related filings
CA2635378 is likely part of a broader patent family, with corresponding applications filed in:
- United States (US)
- European Patent Office (EP)
- World Intellectual Property Organization (PCT)
Examining these filings confirms the scope of protection and provides insights into potential legal strategies and patent strengths.
Competitive landscape
The biological and chemical space surrounding CA2635378 includes:
- Similar compounds in patent literature, particularly in the US and Europe.
- Active development by pharmaceutical competitors targeting identical or related indications.
- Patent thrifting due to prior art in the chemical space, affecting patent enforceability.
Key competitive patents often originate from large pharma entities with extensive patent portfolios covering related molecules and therapeutic methods.
Patentability challenges
Potential challenges for CA2635378 include:
- Prior art conflicts: Existing patents or publications covering similar compounds or uses.
- Obviousness: Similar compounds or methods well-known in the art could threaten patent validity.
- Clarity and enablement: The patent must sufficiently disclose the invention to meet Canadian standards; failure could lead to invalidation.
Key considerations for patent strategy
- Emphasize novel features of the compound or its use.
- Secure broad formulation and use claims to enhance protection.
- File in multiple jurisdictions to build a global patent portfolio.
- Monitor competing patents for freedom-to-operate analysis.
Key Takeaways
- CA2635378 covers a specific chemical entity with claims extending to its pharmaceutical use.
- The scope depends on the claim language, with compound and use claims providing strategic protection.
- The patent landscape in Canada emphasizes novelty, inventive step, and utility.
- Competitors' patents in the same space could challenge validity or enforceability.
- Strategic patent filing and claim drafting are essential to defend therapeutic and formulation claims.
FAQs
1. Can CA2635378 be challenged based on prior art?
Yes. Similar compounds or therapeutic use disclosures before the filing date can be grounds for invalidity actions.
2. How does Canadian patent law affect pharmaceutical patent scope?
It emphasizes clarity, novelty, and inventive step. Claims must be supported by detailed disclosures; vague claims face invalidation.
3. Is there potential to extend protection beyond 20 years for CA2635378?
Yes, through patent term adjustments or pediatric extensions, though Canada has limited mechanisms compared to other jurisdictions.
4. How important are formulation claims in pharmaceutical patents?
Crucial. They can provide a broader scope of protection for drug delivery methods and formulations, complementing compound claims.
5. How does the patent landscape influence R&D investment?
A robust patent portfolio secures competitive advantage, but overlapping patents require careful freedom-to-operate analysis.
References
[1] Canadian Intellectual Property Office. (2023). Patent examination guidelines.
[2] WIPO. (2023). Patent landscape reports.
[3] European Patent Office. (2023). European patent law and practice.
[4] United States Patent and Trademark Office. (2023). Patent examination procedures.
[5] Canadian Patent Act. (2023). R.S.C., 1985, c. P-4.
